Correction: The cytotoxicity of gomesin peptides is mediated by the glycosphingolipid pathway and lipid-cholesterol interactions.
Gomesin peptides keep showing up in research for a reason. A recent correction in Cell Death Discovery reaffirms that their cytotoxic effects—how they take out target cells—come down to two main factors: the glycosphingolipid pathway and lipid-cholesterol interactions. This isn’t just academic nitpicking. Understanding exactly how gomesin peptides interact with cell membranes is the difference between a blunt tool and a precision instrument in peptide research.
Cell Death Discov
by Fernandez-Carrasco I, Moral-Sanz J, Kurdyukov S et al.
“Correction: The cytotoxicity of gomesin peptides is mediated by the glycosphingolipid pathway and lipid-cholesterol interactions. Fernandez-Carrasco I(1), Moral-Sanz J(1), Kurdyukov S(2), Obis È(3), Hartmann LM(4), Magalhães Novais SC(5), Waller MA(2), McKinnon N(2), Chung F(2), Salazar Castejón FJ(1), Rainho DP(1), Dekan Z(6), Kremsmayr T(7), Jandl B(6)(7), Filipič KE(8), Pamplona R(3), Jové M(3), Fernandez-Rojo MA(1)(9), Anderluh G(8), Muttenthaler M(6)(7), Alewood PFA(6), Procházka J(5), Neely GG(2), Deplazes E(4)(10), Ikonomopoulou MP(11)(12). Author information: (1)Madrid Institute for Advanced Studies in Nutrition (IMDEA Nutrition), Madrid, Spain. (2)Dr. John and Anne Chong Lab for Functional Genomics, Charles Perkins Centre and School of Life & Environmental Sciences, The University of Sydney, Sydney, NSW, Australia. (3)Department of Experimental Medicine, Lleida Biomedical Research Institute (IRB Lleida), University of Lleida (UdL), Lleida, Spain. (4)School of Chemistry and Molecular Biosciences, The University of Queensland, St. Lucia, QLD, Australia. (5)Czech Centre for Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences, Vestec, Czechia. (6)Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, Australia. (7)Institute of Biological Chemistry, University of Vienna, Vienna, Austria. (8)Department of Molecular Biology and Nanobiotechnology, National Institute of Chemistry, Ljubljana, Slovenia. (9)Frazer Institute, Translational Research Institute, The University of Queensland, Woolloongabba, QLD, Australia. (10)School of Life Sciences, University of Technology Sydney, Ultimo, NSW, Australia. (11)Madrid Institute for Advanced Studies in Nutrition (IMDEA Nutrition), Madrid, Spain. maria.ikonomopoulou@nutricion.imdea.org. (12)Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, Australia. maria.ikonomopoulou@nutricion.imdea.org. Erratum for Cell Death Discov. 2025 Nov 21;11(1):538. doi: 10.1038/s41420-025-02817-x.”
Here’s what matters:
The glycosphingolipid pathway is a complex cell signaling and membrane domain system. When gomesin peptides hit this pathway, specific cell types can be selectively targeted.
Lipid-cholesterol interactions give these peptides their punch. Cholesterol content in membranes changes how gomesin peptides bind and disrupt cells, which has huge implications for designing next-gen cytotoxic peptides.
Why care? Researchers looking to build on gomesin’s cytotoxic blueprint now have a clearer map. If you’re hunting for cell-selective activity—maybe in cancer cell models or antimicrobial studies—these findings point to membrane composition as a key variable. This is actionable knowledge for anyone tweaking peptide sequences or modifying their research conditions.
Key takeaway: The more we know about how gomesin and similar peptides play with lipid environments, the closer we get to custom-designed, cell-specific research peptides. That’s a win for the whole community.
For more on how peptides are being explored and optimized, check out the peptide research index. If you’re sourcing materials for your own experiments, browse the vendor directory.
Membrane targeting is getting sharper, and gomesin peptides are leading the charge.
Related Reading
Eu(3+)-mediated dual-crosslinked collagen-mimetic peptide/sodium alginate hydrogel for 3D-printed skin wound dressings.
News · Acta BiomaterAntimicrobial-potentiated colorectal cancer therapy with synchronized tumoricidal immunity via a self-deliverable nanopeptide.
News · J Am Pharm Assoc (2003)Real-world weight impact upon tirzepatide discontinuation at a single-center endocrinology clinic in patients with overweight or obesity.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.